Product Details
Tecentriq 1200 mg / 20 mL (Atezolizumab In Pakistan
Tecentriq 1200mg/20ml contains atezolizumab, a programmed death-ligand 1 (PD-L1) blocking antibody used as an immunotherapy medicine for certain types of cancer. It works by blocking PD-L1, helping the immune system recognize and attack cancer cells.
Tecentriq is supplied as a 1200mg/20ml solution in a single-dose vial and is administered by intravenous infusion by qualified healthcare professionals. Depending on the cancer type and treatment plan, it may be used alone or together with other anticancer medicines.
Benefits
- Contains atezolizumab 1200mg.
- PD-L1-targeted immunotherapy.
- Used for specific approved cancer indications.
- Available as a convenient 20ml single-dose vial.
- May be used as monotherapy or in combination with other anticancer treatments when clinically appropriate.
- Approved for selected lung cancers and other specific malignancies.
- Administered under specialist oncology supervision.
Specifications
| Specification | Details |
|---|---|
| Brand | Tecentriq |
| Active Ingredient | Atezolizumab |
| Strength | 1200mg/20ml |
| Concentration | 60mg/ml |
| Dosage Form | Injection / Infusion Solution |
| Route | Intravenous (IV) |
| Container | Single-dose vial |
| Volume | 20ml |
| Drug Class | PD-L1 blocking antibody / Immunotherapy |
| Manufacturer | Genentech / Roche |
| Prescription Status | Prescription medicine |
The official product information describes Tecentriq 1200mg/20ml as a sterile, preservative-free solution supplied in a single-dose vial.
How To Use
Tecentriq must be administered by a qualified healthcare professional in an appropriate medical setting. It is given as an intravenous infusion and should not be self-administered. The FDA prescribing information specifies that the infusion is initially administered over 60 minutes; if tolerated, subsequent infusions may be given over 30 minutes.
The dosing schedule depends on the specific cancer and treatment regimen. For several approved adult indications, 1200mg may be administered every 3 weeks, while other approved schedules include 840mg every 2 weeks or 1680mg every 4 weeks. The oncologist determines the appropriate regimen.
Do not change the dose or treatment schedule yourself. Patients should inform their oncology team about other medicines, previous immune-related problems, autoimmune conditions, pregnancy, or breastfeeding before treatment.
Why Choose Tecentriq?
Tecentriq is an established atezolizumab-based immunotherapy designed to target the PD-L1 pathway. Its approved uses include specific forms of non-small cell lung cancer, small cell lung cancer, hepatocellular carcinoma, melanoma, and alveolar soft part sarcoma, depending on the patient's clinical and diagnostic profile.
The 1200mg/20ml presentation provides a standardized single-dose vial for administration by oncology professionals as part of an individualized cancer-treatment plan.
